Advertisement


Related Videos

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Peter Clark, MA, MD, FRCP: A Payer Perspective

Opportunities to Optimize Cancer Policies Panel Discussion

Advertisement

Advertisement




Advertisement